Fred Driscoll
Director/Board Member bij CUE BIOPHARMA, INC.
Vermogen: 15 229 $ op 31-03-2024
Profiel
Frederick W.
Driscoll currently works at MEI Pharma, Inc., as Independent Non-Executive Director from 2018, Calliditas Therapeutics AB, as Director from 2023, Cellectar Biosciences, Inc., as Independent Director from 2017, Cue Biopharma, Inc., as Independent Director from 2018, SmartPharm Therapeutics, Inc., as Director from 2019, and NeoSoma, Inc., as Director from 2023.
Mr. Driscoll also formerly worked at Oncotelic Therapeutics, Inc., as Chairman, President & Chief Executive Officer from 2000 to 2006, Genelabs Technologies, Inc., as President & Chief Executive Officer from 2008 to 2009, NantKwest, Inc., as Lead Independent Director, Cynapsus Therapeutics, Inc., as Director in 2016, Abpro Corp., as Independent Director, ImmunityBio, Inc., as Director, Novavax, Inc., as Chief Financial Officer, Treasurer & VP from 2012 to 2013, ConforMIS, Inc., as Chief Financial Officer & Treasurer from 2019 to 2020, Flexion Therapeutics, Inc., as Chief Financial Officer from 2013 to 2017, Flexion Therapeutics, Inc., as Chief Financial Officer in 2021, Instrumentation Laboratory Co., as Vice President-Finance-Americas & Controller from 1974 to 2006, Astraris, Inc., as Chief Financial Officer from 2006 to 2007, Collagenesis Corp., as Senior Vice President-Finance & Operations from 1996 to 2000, Invivyd, Inc., as Chief Financial & Accounting Officer from 2022 to 2023, and Renovacor, Inc., as Secretary, Chief Financial & Accounting Officer.
Mr. Driscoll received his undergraduate degree in 1972 from Bentley University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-09-2023 | 1 942 ( 0.02% ) | 7 729 $ | 31-03-2024 | |
MEI PHARMA, INC.
0.03% | 30-10-2023 | 1 875 ( 0.03% ) | 7 500 $ | 31-03-2024 |
CUE BIOPHARMA, INC.
-.--% | 02-01-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Fred Driscoll
| Bedrijven | Functie | Begin |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Director/Board Member | 07-04-2017 |
| MEI PHARMA, INC. | Director/Board Member | 26-02-2018 |
| CUE BIOPHARMA, INC. | Director/Board Member | 26-06-2018 |
| CALLIDITAS THERAPEUTICS AB | Director/Board Member | 30-05-2023 |
NeoSoma, Inc.
 NeoSoma, Inc. Packaged SoftwareTechnology Services NeoSoma, Inc. is a private company that specializes in developing innovative software products that utilize artificial intelligence to improve the treatment of brain cancers. The company is based in Groton, MA. The company also offers a clinical management software platform. The company was founded by Aly Abayazeed. The CEO is Kenneth Kolodziej. | Director/Board Member | 15-03-2023 |
SmartPharm Therapeutics, Inc.
 SmartPharm Therapeutics, Inc. BiotechnologyHealth Technology SmartPharm Therapeutics, Inc. engages in the development of next-generation, non-viral gene therapies for the treatment of serious or rare diseases. Its pipeline include Gene MAbs for SARS-Cov-2, enzyme replacement therapy, and cell and tissue restoration. The company was founded by José Trevejo in 2017 and is headquartered in Cambridge, MA. | Director/Board Member | 05-09-2019 |
Eerdere bekende functies van Fred Driscoll
| Bedrijven | Functie | Einde |
|---|---|---|
| INVIVYD, INC. | Director of Finance/CFO | 01-09-2023 |
| RENOVACOR, INC. | Director of Finance/CFO | 17-06-2022 |
| FLEXION THERAPEUTICS, INC. | Director of Finance/CFO | 19-11-2021 |
| ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Fred Driscoll
| Bentley University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 9 |
|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| NOVAVAX, INC. | Health Technology |
| CONFORMIS, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| CALLIDITAS THERAPEUTICS AB | Health Technology |
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| CUE BIOPHARMA, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| IMMUNITYBIO, INC. | Health Technology |
| Bedrijven in privébezit | 11 |
|---|---|
Genelabs Technologies, Inc.
 Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Health Technology |
NantKwest, Inc.
 NantKwest, Inc. BiotechnologyHealth Technology NantKwest, Inc. engages in the research and development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA. | Health Technology |
Cynapsus Therapeutics, Inc.
 Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada. | Health Technology |
Abpro Corp.
 Abpro Corp. BiotechnologyHealth Technology Abpro Corp. operates as a biotechnology company which develops antibody therapeutics for severe and life threatening diseases. It focusses on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. The company was founded by Ian Chan and Eugene Y. Chan in 2007 and is headquartered in Woburn, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Instrumentation Laboratory Co.
 Instrumentation Laboratory Co. Medical SpecialtiesHealth Technology Instrumentation Laboratory Co. manufactures diagnostic products. It offers critical care systems, hemostatis products and information management services. The firm provides services to the hospitals and clinical laboratories. Instrumentation Laboratory was founded in 1959 and is headquartered in Bedford, MA. | Health Technology |
| Astraris, Inc. | |
Collagenesis Corp.
 Collagenesis Corp. Other Consumer ServicesConsumer Services Collagenesis Corp. operates a beauty salon. The private company is based in Beverly, MA. | Consumer Services |
SmartPharm Therapeutics, Inc.
SmartPharm Therapeutics, Inc. BiotechnologyHealth Technology SmartPharm Therapeutics, Inc. engages in the development of next-generation, non-viral gene therapies for the treatment of serious or rare diseases. Its pipeline include Gene MAbs for SARS-Cov-2, enzyme replacement therapy, and cell and tissue restoration. The company was founded by José Trevejo in 2017 and is headquartered in Cambridge, MA. | Health Technology |
NeoSoma, Inc.
NeoSoma, Inc. Packaged SoftwareTechnology Services NeoSoma, Inc. is a private company that specializes in developing innovative software products that utilize artificial intelligence to improve the treatment of brain cancers. The company is based in Groton, MA. The company also offers a clinical management software platform. The company was founded by Aly Abayazeed. The CEO is Kenneth Kolodziej. | Technology Services |
Renovacor, Inc.
 Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
